Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes

Jennifer K. Garrett(Cincinnati Children's Hospital Medical Center), Joshua A. Boyce(Brigham and Women's Hospital), Debbie K Freese(Mayo Clinic), Joyce Villanueva(Cincinnati Children's Hospital Medical Center), Margaret H. Collins(Cincinnati Children's Hospital Medical Center), Lisa A. Beck(University of Rochester Medicine), Blythe Thomson(Epizyme (United States)), Lynne E. Wagoner(University of Cincinnati), Sean C. Jameson(Cincinnati Children's Hospital Medical Center), Alexandra H. Filipovich(Carolinas Medical Center)
Journal of Allergy and Clinical Immunology
January 1, 2004
10.1016/j.jaci.2003.10.049
Cited by 364

Related Papers

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
|Cell|2020|2.5k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k